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C-terminally deleted analogs of human interleukin-6 (IL-6) have been constructed at the cDNA level, and after cell-free transcription and translation 
their biological activity was analyzed. Removal of only 4 amino acids resulted in complete loss of biological activity as determined by the B9 cell 
proliferation assay. Secondary structure prediction of human IL-6 resulted in 58% helix, 14% ~-structure, and 28% turn and coil (average of 3 inde 
pendent methods). The circular dichroism of recombinant human IL-6 was measured in the near and far W. Evaluation of the latter in terms 
of secondary structures gave 67% helix, 15% /?-structure, and 18% turn and coil. 
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1. INTRODUCTION ty. In addition information on the secondary structure 
of human IL-6 is presented. 
Interleukins are a group of signalling molecules in- 
volved in the communication between cells. They are 
produced and secreted by many different cell types, 
particularly by those of the immune system. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Interleukin-6 (IL-6) elicits a wide spectrum of 
biological functions. In general, IL-6 represents a 
growth and differentiation factor acting on B-cells, T- 
cells, lymphoma cells, hybridoma/plasmacytoma cells, 
hematopoietic stem cells, and hepatocytes (for reviews 
see [1,2]). 
L-[3’S]methionine (> 37 TBq/mmol) and 6-[3H]thymidine (74 
GBq/mmol) were purchased from Amersham International (Amer- 
sham, UK). Except for exonuclease III (E. co/r), which was from AGS 
(Heidelberg, FRG), enzymes were obtained from Boehringer (Mann- 
heim, FRG). 
2.2. Constructi5n of IL-6 deferion mutants 
IL-6 consists of 184 amino acids [3]. It is synthesized 
as a larger polypeptide precursor with a signal peptide 
of 28 amino acids. The native molecule is N- and O- 
glycosylated and may also be phosphorylated [4-61. 
It is believed that IL-6 exerts its action via a specific 
receptor on the surface of the various target cells [7]. 
The IL-6 receptor has recently been cloned and se- 
quenced [S]. Thus far, nothing is known about the 
underlying mechanisms for the signal transduction 
following the binding of IL-6 to its specific plasma 
membrane receptor. In order to understand the interac- 
tion of IL-6 with its receptor, it is important to obtain 
some information on structural features essential for its 
biological function. As a first approach we have con- 
structed IL-6 mutants lacking various portions of the 
carboxy-terminus and evaluated their biological activi- 
pGEM 3 containing the complete coding region of IL-6 was step- 
wise truncated at the 3 ‘-end using the method described in [91. After 
sequencing, deletions were selected, which after in vitro transcription 
and translation resulted in polypeptides lacking 4, l&26, 36 and 48 
amino acids at the C-terminus. The linearized plasmids were 
transcribed with T7 RNA polymerase and subsequently translated in 
a cell-free system (rabbit reticulocyte lysate) in the presence of [35S]- 
methionine [lOI. After SDS-PAGE the cell-free synthesized polypep- 
tides were excised from the polyacrylamide gel and their radioactivity 
was determined. 
2.3. IL-6 assay 
The IL-6 assay was performed using the ILL-de~ndent murine 
plasmacytoma cell line I39 kindly provided by L. Aarden (Amster- 
dam, The Netherlands) [i 11. 
2.4. Circular dichroism (CD) measurements 
Correspondence address: A. Krtittgen, Institut fur Biochemie der 
RWTH Aachen, Pauwehstrasse 30, D-5100 Aachen, FRG 
CD measurements were carried out on an AVIV CD spectrometer 
62DS prototype. The instrument was calibrated with a 0.1% aqueous 
solution of d-l~c~phorsulphonic acid (&& ‘2” = 0.308’). The 
ratio I 8392.5 m/ I ~92~3 nm I was 1.90. The temperature was lO’C, the 
spectral bandwidth 1.5 nm. The protein concentration was based on 
amino acid analysis. The absorption coefficient calculated with this 
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1 g/l. 1 cm 
concentration was A278 ,,,,, = 0.652. The CD spectrum in the far 
UV was analyzed with respect o the main chain conformation of IL-6 
with the CONTIN program [12]. 
Secondary structure predictions according to Garnier, Osguthorpe 
and Robson (GOR) [13] and Chou and Fasman [14] were performed 
with the computer program package GENMON (version 4.1, 1989; 
kindly provided by GBF, Braunschweig, FRG). The predictive rules 
of Chou and Fasman [14] were used in order to decide alternatives in 
the output of the program. The GGBSM program of Gasquel and 
Golmard [15] was used independently. 
3. RESULTS AND DISCUSSION 
The cDNA containing the complete coding region of 
the human IL-6 was truncated at the 3 ‘-end. After cell- 
free transcription and translation, 5 mutant polypep- 
tides lacking 4, 15, 26, 36 and 48 amino acids at the C- 
terminus were obtained. Fig. 1 shows the increased elec- 
trophoretic mobilities of the [35S]-methionine-labelled 
IL-6 mutants in comparison to the full-length IL-6 (co), 
also synthesized by in vitro transcription and transla- 
tion. 
The various IL-6 forms were tested for their bio- 
logical activity in the B9 cell assay. Since higher concen- 
trations of the reticulocyte lysate interfered with the 
IL-6 assay, equal and subtoxic volumes of the transla- 
tion mixture were used. The measured IL-6 activities 
were compared by taking into account the radioactivity 
incorporated and the number of methionine residues 
present in the mutant polypeptides (see insert of fig.2). 
It is clearly seen in fig.2 that the removal of only 4 
amino acids is sufficient to abolish essentially all 
biological activity. As expected, the IL-6 mutants A 15, 
426, A36 and A48 did not exert any biological activity 
either under our assay conditions. 
In order to obtain a first idea of the molecule’s struc- 
tural make-up, 3 different methods were used to predict 
secondary structure from the amino acid sequence [3]. 
The average fractions obtained are 58% helix, 14% /3- 
structure and 28% turn and coil. As can be seen in fig.3, 
there are 8 regions where a helical structure is predicted 
conformably by all 3 methods: positions 37-41, 53-62, 
67-68,92-101, 111-120, 127-133, 156-160, 174-181. It 
should be noted that all 3 methods predict an a-helix at 
the C-terminus of human IL-6. 
In order to determine the a-helix content of rhIL-6, 
CD measurements were performed. The CD spectrum 
of rhIL-6 in the far UV (fig.4A) is characteristic of that 
of a protein with a high helix content. The analysis with 
the CONTIN program [ 121 results in 67% a-helix, 15 % 
&structure and 18% turn and coil. Fig.4b shows the CD 
spectrum in the near UV. The main band is due to 
tyrosine and the long region tailing off towards longer 
wavelengths eems to represent a background from the 
disulphide chromophore. The latter may also be 
responsible for the hesitantly positive ellipticity at 253 
nm [17]. 
Agreement of experiment and prediction with respect 
to the percentage of helix is best for the GOR method 
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Fig. 1. SDS-PAGE of cell-free synthesized IL-6 mutants truncated at 
the carboxy-terminus. Full length IL-6 and truncated forms of it ob- 
tained after in vitro transcription and translation were separated by 
SDS-polyacrylamide gel (12.5%) electrophoresis and visualized by 
fluorography [16]. ‘co’ represents the full length IL-6 control; 44, 
A15,426,436, A48 denote the IL-6 polypeptides lacking 4,15,26,36, 
48 amino acids from the carboxy-terminus, respectively. 
(67% vs 69%). On the other hand, helices of some 40 
residues in length as predicted by this method (see fig.3) 
are unusual. Their continuity is also questionable in 
view of the two other predictions and of the incom- 
patibility with the 44-50 cystine bridge. 
The high helix content of human IL-6 is in contrast o 
the structures of IL-W [18] and TNFa [19]. IL-Ifl is 
composed of 12 P-strands forming a tetrahedron core 
structure, where all 6 edges consist of 2 antiparallel fl- 
strands [ 181. Tumor necrosis factor (Y (TNFcu) is a 
trimeric molecule, each subunit of which consists of an 
antiparallel P-sandwich [ 191. From our experiments 
presented in fig.2, it is clear that the 4 carboxy-terminal 
amino acids of the human IL-6 are essential for the 
biological activity of this cytokine. Comparison of 
these 4 amino acids with the amino acid sequences at the 
co 
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Fig.2. Biological activity of IL-6 mutant polypeptides. One Cl of each 
translation mixture was used for IL-6 activity determinations. The ob- 
tained values were normalized on the basis of the incorporated 
radioactivity and the number of methionine residues present in the 
mutant polypeptides as shown in the schematic representation i  the 
insert. For the full-length IL-6, maximal incorporation of 
[‘Hlthymidine into DNA was 8000 cpm = 100% per well containing 
5 x 10’ cells. 
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Fig.3. Secondary structure of human IL-6 as predicted by the methods of Chou and Fasmann (CF), Gasquel and Golmard (GGBSM), and Gamier, 
Osguthorpe and Robson (GOR). Helical segments are indicated by I, @sheet by M and turn by n. The positions of the cysteine residues 
are indicated (c). 
C-termini of mouse [20] and rat [21] IL-6 shows that 2 
residues are completely conserved: human = Leu-Arg- 
Gln-Met, and mouse = rat = Thr-Arg-Gln-Thr. It is 
conceivable that these 4 amino acid residues either form 
the binding site or part of it, or are important for the 
Fig.4. CD spectra or recombinant human IL-6 in the far (a) and near 
(b) UV. Concentration: 0.34 g/l; solvent: 10 mM phosphate buffer, 
pH 7; pathlengths: 0.02, 0.1 and 2 cm. 
maintenance of structural requirements for receptor- 
ligand interaction. In particular, the positive charge of 
arginine could be essential. Our observations are in ac- 
cordance with recent results of Ida et al. [22]. These 
authors described a neutralizing monoclonal antibody, 
which binds to the carboxy-terminal part of human 
IL-6 (Ala 153-Thr 162). Interestingly the exchange of 
Trp 157 to Arg by site-directed mutagenesis had no ef- 
fect on the biological activity (Moller et al., unpublish- 
ed results). Brackenhoff et al. [23] described the first 28 
amino acids of human IL-6 as not being essential for 
biological activity. A detailed understanding of the 
structure-function relationship of IL-6 has to await the 
elucidation of the 3-dimensional structure by X-ray 
analysis. 
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